Xencor enters its August 4 earnings report in an unusual position: a 33% rally over the past month has stripped out a meaningful chunk of short positioning, while options traders have swung to their most bullish reading in months — a setup that cuts against the elevated short interest still on the books.
The most striking shift this week is in options sentiment. The put/call ratio has collapsed to 0.31, almost 1.4 standard deviations below its 20-day average of 0.98, and near the lowest reading of the past year. For most of June and the first half of July, the PCR was running above 1.3 — heavily skewed toward downside protection. That regime ended abruptly around July 20, when calls began dominating flow. The reversal is sharp enough that it reads as deliberate repositioning ahead of the August 4 print, not noise.
Short interest at 15.3% of the free float is still high in absolute terms. But the direction matters: shorts have pulled back roughly 5% over the past week, with covered positions bringing the share count down from around 11.5 million to 10.9 million. Borrow availability remains generous at 316% — meaning there are more than three shares available to borrow for every one currently lent out — so there is no squeeze mechanics building in the lending market. Cost to borrow has climbed 28% over the week to 0.66%, a one-month high, but the absolute level remains trivially low. The days-to-cover reading of 13.6 days from the latest FINRA settlement is worth noting — that's a long runway for any forced covering — but with borrow this loose, there is nothing in the lending setup that looks stressed.
The Street is divided in a way that maps onto the stock's own ambiguity. Truist Securities maintained its Buy rating on July 7 but trimmed its target to $27 from $29, while JP Morgan holds at Neutral with a $14 target — implying the stock is already past fair value at $19.97. The consensus mean target of $28.33 implies roughly 42% upside from current levels, but the spread between the bull case ($27-$42 range) and the bear case ($14) is wide enough to reflect genuine clinical uncertainty rather than a valuation debate. The bull thesis rests on the TL1A×IL23p19 program and royalty ramp from Ultomiris and Monjuvi. Bears point to documented dosing errors, a 73% cytokine release syndrome rate in one trial cohort, and the risk that pipeline setbacks push the stock back toward its cash value. The ORTEX short score has drifted up steadily to 72.2, a multi-week high, reflecting the combination of elevated SI and a stock that has run hard into a binary catalyst.
The institutional ownership picture adds one genuinely notable data point. BlackRock added 1.1 million shares as of June 30, lifting its stake to 17.6% of shares. RA Capital — a specialist healthcare fund — reported a new position of 4.9 million shares at March 31, accounting for 6.6% of the company. The cluster of specialist biotech holders (BVF Partners at 9.6%, RTW Investments at 9.1%) alongside generalist passive flows suggests conviction from investors with the expertise to price clinical risk, though those filings predate the recent price surge by several months.
The prior three earnings prints show a wide range of outcomes: a 14.7% gap higher in February, a 3.9% bounce in May, and a separate 4.2% drop. The five-day drift has been similarly mixed, with one episode ending down nearly 9%. The August 4 release is an after-hours event, which means the options repricing will happen overnight — and with the PCR at its most call-heavy level all year, the positioning asymmetry is pointed firmly at upside surprise.
What to watch: whether the short score — currently edging toward its highest reading of the tracked period — continues its steady climb into and through the earnings date, or reverses sharply on any pipeline commentary that resolves the clinical uncertainty around the CRS rate data.
See the live data behind this article on ORTEX.
Open XNCR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
